Bluejay Diagnostics, Inc. (BJDX) News
Filter BJDX News Items
BJDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BJDX News From Around the Web
Below are the latest news stories about BLUEJAY DIAGNOSTICS INC that investors may wish to consider to help them evaluate BJDX as an investment opportunity.
Bluejay Diagnostics Announces Reverse Stock SplitACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time |
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public OfferingACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Co |
Top Midday DeclinersTop Midday Decliners |
Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public OfferingACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Co |
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis PatientsResults from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed |
BJDX: 1Q:24 Financial UpdateBy John Vandermosten, CFA NASDAQ:BJDX Bluejay Diagnostics, Inc. (NASDAQ:BJDX) reported first quarter 2024 operational and financial results in a Form 10-Q on May 15th, 2024. Pilot study SYMON-I is underway and has completed enrollment, with 143 subjects entering the trial. Based on the recruitment information in SYMON-I’s clincaltrials.gov entry and management commentary, we expect the final data |
BJDX: 2023 Financial UpdateBy John Vandermosten, CFA NASDAQ:BJDX Bluejay Diagnostics, Inc. (NASDAQ:BJDX) reports full year 2023 results capping a year that saw substantial interaction with the FDA determining a new trial design. The endpoint for Bluejay’s previous trial sought to determine IL-6 concentration in patients with COVID and to predict the need for mechanical ventilation. With fewer COVID cases, the endpoint |